



Mundipharma at a glance



\$1.64bn USD
in Sales*



Headquartered in Cambridge UK, with a presence across Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East.



Global leader in Pain Management.
Global Consumer Health portfolio.



Pipeline includes *rezafungin* in Phase III and *tinostamustine* in Phase I clinical development.



Over 2600 employees

Capabilities across Commercial, Market Access, Manufacturing and Supply Chain.

Partner of choice to commercialise Specialty Care products.

Clear business model based on Commercial Excellence.



3572 Marketing Authorisations

Experience in late-phase development and in leading global, multi-centre clinical trials in Specialty Care.

Therapy areas include anti-infectives, biosimilars, central nervous system (CNS), oncology, ophthalmology and respiratory.